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We have recently published a meta-analysis of 8 randomized controlled trials (RCTs) including 2,128 
women and described that intravaginal or intracervical application of ejaculate and seminal plasma 
(SP) around the time of oocyte aspiration and/or embryo transfer in IVF therapies significantly 
increased clinical pregnancy rate (RR 1.20, 95% CI 1.04–1.39) (1). These results confirmed and 
extended an earlier meta-analysis which had also shown significantly improved outcomes when 
women are exposed to SP around the time of ovum pick-up or embryo transfer with statistical 
significance for clinical pregnancy rate (2). In our meta-analysis, we had added a subgroup analysis 
with 4 RCTs including 780 participants in which prepared undiluted SP was injected intravaginally/
intracervically just after oocyte aspiration. This analysis revealed an increased pregnancy rate in 
women treated with SP (RR 1.23, 95% CI 1.05–1.45) (1), an effect that seems to be independent from 
the quality of sperm count (3). By contrast, intrauterine application of diluted SP did not show any 
positive effect (4).
Therefore, local application of undiluted SP or its constituents can now be considered as a 
straightforward, non-invasive, and rather cheap treatment to improve implantation in IVF. The 
rationale of this treatment is the modulation of endometrial function (5), which has been shown to 
be negatively affected in IVF (6). Furthermore, SP might positively modulate the maternal immune 
system to better accept the semi-allogenic embryo (7).
Therefore, this approach could be considered to be integrated in daily practice in IVF with fresh 
embryo transfer. However, this raises the question of which approach would most reasonably be 
expected to yield the highest effect with the lowest cost and burden for the couple, the IVF laboratory, 
and the physician.
Four options could be considered:
 1. Defined constituents of SP such as TGFβ are used instead of prepared SP.
 2. The couple is instructed to have intercourse around the time of follicle aspiration and/or embryo 
transfer.
 3. Undiluted SP is injected into the vagina/cervix just after follicle aspiration.
 4. Diluted SP is injected into the vagina/cervix just after follicle aspiration.
Ad 1: In mice it has been shown that the most relevant constituent in SP is TGFβ (8). TGFβ 
has immune-deviating properties which favor implantation (9). In humans, TGFβ is also a major 
constituent of SP which influences cervical immune function in vitro (10). Accordingly, using TGFβ 
instead of SP appears to be a straightforward option as TGFβ seems to play a role in the modulation 
of the immune response and thereby possibly improve implantation. However, TGFβ has only been 
proven in mice to play a role in implantation but convincing data in humans regarding implantation 
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are still missing. Furthermore, Gutsche et al. (5) have shown in 
humans that although TGFβ seems to play an important role it 
is rather the combination of several constituents which provokes 
the implantation improving effect. This is in line with Sharkey 
et al. (10) who demonstrated that although TGFβ is able to induce 
the production of IL-6 and GM-CSF in cervical cells the induc-
tion of several other cytokines is not related to TGFβ. Therefore, 
substituting SP by specific SP constituents might be an option but 
could result in lower efficacy.
Ad 2: This option seems to be the easiest one. However, the 
abovementioned subgroup analysis studying the application 
of undiluted SP into the vagina/cervix revealed a significantly 
improved pregnancy rate, whereas an RCT analyzing the effect of 
intercourse did not find a significant difference (11). Tremellen 
et  al. (11) did find a higher proportion of viable embryos, but 
the pregnancy rate was not higher in the intercourse group. 
This suggests that intercourse might increase the likelihood of 
early embryo implantation but that vaginal/cervical application 
of undiluted SP is more effective. Furthermore, as intercourse 
after ovarian hyperstimulation can be expected to be painful and 
as there is a risk of multiples if not all follicles were aspirated, 
the application of SP seems to be more effective and safer than 
intercourse.
Ad 3: This option involves the collection and preparation of SP a 
few days or weeks before aspiration followed by cryopreservation, 
as described by the first pilot by von Wolff et al. (12), requiring an 
extra consultation of the male and an extra effort and additional 
costs for the lab. For this approach, semen samples should be 
obtained from the patient’s partner by masturbation, at least a 
half-week before follicle aspiration, and collected into sterile 
flasks. SP is then extracted by centrifugation and cryopreserved 
until instilled into the female tract at the time of follicle aspiration 
or embryo transfer (12). As the approach had been chosen by the 
other clinical studies included in the abovementioned subgroup 
analysis, it can be expected to be effective.
Ad 4: Option 3 also raises the question as to whether it is 
perhaps possible to avoid the freezing of SP a few days or weeks 
before aspiration. For example, small amounts of fresh SP, isolated 
from the ejaculate used for the IVF/ICSI procedure on the day of 
follicle aspiration, could be collected before density centrifuga-
tion to prepare it for intravaginal/intracervical application. This 
approach may be achievable in men with sufficiently high sperm 
concentrations and ejaculate volume; however, in men with low 
sperm concentrations or low ejaculate volume, this would not 
be possible. This option would avoid an extra consultation with 
the male partner and thereby better integrate this procedure into 
daily IVF practice. However, in men with a low sperm count and/
or semen volume, the whole ejaculate volume would be needed 
for sperm preparation, and the SP collected after density centrifu-
gation will contain a substantial amount of preparation medium 
with unknown effects on the activity of SP and the female genital 
tract. Furthermore, this option would increase the workload 
for the lab at a time when the lab is already maximally involved 
with follicle aspiration and oocyte preparation. There are more 
points which question this approach. First, Gutsche et  al. (5) 
found that the stimulatory effect of SP decreased with lower SP 
concentrations, questioning the effect of low SP concentrations. 
Clinically, this was confirmed by von Wolff et al. (4), who did not 
find any positive effect with intrauterine instillation of 1:5 diluted 
SP. Furthermore, the concentration of active constituents such as 
cytokines varies considerably in SP as shown by Huleihel et al. 
(13) and others. Therefore, the implantation improving effect 
might be even lower in some subjects with low concentration 
of active constituents. Therefore, this approach does not seem to 
be feasible.
In conclusion, the application of undiluted SP seems to be 
more effective and safer than intercourse at the time of follicle 
aspiration. SP should, to be used in daily practice, be isolated 
and prepared at least a few days before oocyte aspiration and 
used without any dilution. Determination of the most beneficial 
time for instillation of undiluted SP during an IVF/ICSI cycle is 
another important parameter to be considered in future RCTs. 
More research is required before modifications of this approach 
such as the use of specific SP constituents or of diluted SP can 
be recommended. Further RCTs should be encouraged to 
confirm the positive effect of diluted/undiluted SP and to better 
understand under what circumstances this treatment has the best 
clinical outcome.
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